Skip to main content
Log in

Aspirin-Induced Asthma

Clinical Aspects, Pathogenesis and Management

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Aspirin (acetylsalicylic acid)-induced asthma (AIA) consists of the clinical triad of asthma, chronic rhinosinusitis with nasal polyps, and precipitation of asthma and rhinitis attacks in response to aspirin and other NSAIDs. The prevalence of the syndrome in the adult asthmatic populations is approximately 4–10%. Respiratory disease in these patients may be aggressive and refractory to treatment.

The aetiology of AIA is complex and not fully understood, but most evidence points towards an abnormality of arachidonic acid (AA) metabolism. Cyclo-oxygenase (COX), the rate-limiting enzyme in AA metabolism, exists as two main isoforms. COX-1 is the constitutive enzyme responsible for synthesis of protective prostanoids, whereas COX-2 is induced under inflammatory conditions. A number of theories regarding its pathogenesis have been proposed. The shunting hypothesis proposes that inhibition of COX-1 shunts AA metabolism away from production of protective prostanoids and towards cysteinyl leukotriene (cys-LT) biosynthesis, resulting in bronchoconstriction and increased mucus production. The COX-2 hypothesis proposes that aspirin causes a structural change in COX-2 that results in the generation of products of the lipoxygenase pathway. It is speculated that this may result in the formation of mediators that cause respiratory reactions in AIA.

Related studies provide evidence for abnormal regulation of the lipoxygenase pathway, demonstrating elevated levels of cys-LTs in urine, sputum and peripheral blood, before and following aspirin challenge in AIA patients. These studies suggest that cys-LTs are continually and aggressively synthesised before exposure to aspirin and, during aspirin-induced reactions, acceleration of synthesis occurs. A genetic polymorphism of the LTC4S gene has been identified consisting of an A to C transversion 444 nucleotides upstream of the first codon, conferring a relative risk of ALA of 3.89. Furthermore, carriers of the C444 allele demonstrate a dramatic rise in urinary LTE4 following aspirin provocation, and respond better to the cys-LT antagonist pranlukast than A444 homozygotes.

AIA patients have an aggressive form of disease, and treatment should include combination therapy with inhaled corticosteroids, β2-adrenoceptor agonists and LT modifiers. Furthermore, recently developed inhibitors of COX-2 may be safer in patients with AIA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Samter M, Beers RF. Intolerance to aspirin: clinical studies and consideration of its pathogenesis. Ann Intern Med 1968; 68: 975–83

    PubMed  CAS  Google Scholar 

  2. Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002; 89(5): 474–8

    Article  PubMed  Google Scholar 

  3. Kasper L, Sladek K, Duplaga M, et al. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy 2003; 58(10): 1064–6

    Article  PubMed  CAS  Google Scholar 

  4. Vally H, Taylor ML, Thompson PJ. The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Thorax 2002; 57(7): 569–74

    Article  PubMed  CAS  Google Scholar 

  5. Nizankowska E, Bestynska-Krypel A, Cmiel A, et al. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J 2000; 15(5): 863–9

    Article  PubMed  CAS  Google Scholar 

  6. Alonso-Llamazares A, Martinez-Cocera C, Dominguez-Ortega J, et al. Nasal provocation test (NPT) with aspirin: a sensitive and safe method to diagnose aspirin-induced asthma (AIA). Allergy 2002; 57(7): 632–5

    Article  PubMed  CAS  Google Scholar 

  7. Milewski M, Mastalerz L, Nizankowska E, et al. Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma. J Allergy Clin Immunol 1998 May; 101(5): 581–6

    Article  PubMed  CAS  Google Scholar 

  8. Casadevall J, Ventura P-J, Mullol J, et al. Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry. Thorax 2000; 55: 921–4

    Article  PubMed  CAS  Google Scholar 

  9. Schlumberger HD. Drug-induced pseudo-allergic syndrome as exemplified by acetylsalicylic acid intolerance. Basel: Karger, 1980: 125–203

    Google Scholar 

  10. Nasser SM, Pfister R, Christie PE, et al. Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Am J Respir Crit Care Med 1996; 153(1): 90–6

    PubMed  CAS  Google Scholar 

  11. Hamilos DL, Leung DY, Wood R, et al. Eosinophil infiltration in nonallergic chronic hyperplastic sinusitis with nasal polyposis (CHS/NP) is associated with endothelial VCAM-1 upregulation and expression of TNF-alpha. Am J Respir Cell Mol Biol 1996; 15(4): 443–50

    PubMed  CAS  Google Scholar 

  12. Cowburn AS, Sladek K, Soja J, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998; 101(4): 834–46

    Article  PubMed  CAS  Google Scholar 

  13. Szczeklik A, Sladek K, Dworski R, et al. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1996; 154 (6 Pt 1): 1608–14

    PubMed  CAS  Google Scholar 

  14. Mastalerz L, Sanak M, Szczeklik A. Serum interleukin-5 in aspirin-induced asthma. Clin Exp Allergy 2001; 31(7): 1036–40

    Article  PubMed  CAS  Google Scholar 

  15. Sanak M, Bazan-Soch S, Szczeklik A. Leukotriene C4 synthase expression in blood eosinophils of patients with asthma. Eur Respir J 1998; 12 Suppl. 28: 373s

    Google Scholar 

  16. Nakagawa H, Yoshida S, Nakabayashi M, et al. Possible relevance of virus infection for development of analgesic idiosyncrasy. Respiration 2001; 68(4): 422–4

    Article  PubMed  CAS  Google Scholar 

  17. Szczeklik A, Nizankowska E, Serafin A, et al. Autoimmune phenomena in bronchial asthma with special reference to aspirin intolerance. Am J Respir Crit Care Med 1995; 152 (6 Pt 1): 1753–6

    PubMed  CAS  Google Scholar 

  18. Lassalle P, Delneste Y, Gosset P, et al. T and B cell immune response to a 55-kDa endothelial cell-derived antigen in severe asthma. Eur J Immunol 1993; 23(4): 796–803

    Article  PubMed  CAS  Google Scholar 

  19. Szczeklik A, Musial J, Pulka G. Autoimmune vasculitis and aortic stenosis in aspirin-induced asthma (AIA). Allergy 1997; 52(3): 352–4

    Article  PubMed  CAS  Google Scholar 

  20. Dekker JW, Nizankowska E, Schmitz-Schumann M, et al. Aspirin-induced asthma and HLA-DRB1 and HLA-DPB1 genotypes. Clin Exp Allergy 1997; 27(5): 574–7

    Article  PubMed  CAS  Google Scholar 

  21. Szczeklik A. Aspirin-induced asthma as a viral disease. Clin Allergy 1988; 18(1): 15–20

    Article  PubMed  CAS  Google Scholar 

  22. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure and expression. Proc Natl Acad Sci U S A 2002; 99: 13926–31

    Article  PubMed  CAS  Google Scholar 

  23. Pang L. COX-2 expression in asthmatic airways: the story so far. Thorax 2003; 56: 335–6

    Article  Google Scholar 

  24. Schwab JM, Schluesener HJ, Laufer S. COX-3: just another COX or the solitary elusive target of paracetamol? Lancet 2003; 361(9362): 981–2

    Article  PubMed  Google Scholar 

  25. Holtzman MJ. Arachidonic acid metabolism: implications of biological chemistry for lung function and disease. Am Rev Respir Dis 1991; 143(1): 188–203

    PubMed  CAS  Google Scholar 

  26. Holgate ST, Burns GB, Robinson C, et al. Anaphylactic- and calcium-dependent generation of prostaglandin D2 (PGD2), thromboxane B2, and other cyclooxygenase products of arachidonic acid by dispersed human lung cells and relationship to histamine release. J Immunol 1984; 133(4): 2138–44

    PubMed  CAS  Google Scholar 

  27. Churchill L, Chilton FH, Resau JH, et al. Cyclooxygenase metabolism of endogenous arachidonic acid by cultured human tracheal epithelial cells. Am Rev Respir Dis 1989; 140(2): 449–59

    Article  PubMed  CAS  Google Scholar 

  28. Pang L, Knox AJ. Effect of interleukin-1 beta, tumour necrosis factor alpha and interferon gamma on the induction of cyclooxygenase-2 in cultured human airway smooth muscle cells. Br J Pharmacol 1997; 121(3): 579–87

    Article  PubMed  CAS  Google Scholar 

  29. Belvisi MG, Saunders MA, Haddad el-B, et al. Induction of cyclooxygenase-2 by cytokines in human cultured airway smooth muscle cells: novel inflammatory role of this cell type. Br J Pharmacol 1997; 120(5): 910–6

    Article  PubMed  CAS  Google Scholar 

  30. Pang L, Pitt A, Petkova D, et al. The COX-l/COX-2 balance in asthma. Clin Exp Allergy 1998; 28(9): 1050–8

    Article  PubMed  CAS  Google Scholar 

  31. Kuehl Jr FA, Dougherty HW, Ham EA. Interactions between prostaglandins and leukotrienes. Biochem Pharmacol 1984; 33(1): 1–5

    Article  PubMed  CAS  Google Scholar 

  32. Christman BW, Christman JW, Dworski R, et al. Prostaglandin E2 limits arachidonic acid availability and inhibits leukotriene B4 synthesis in rat alveolar macrophages by a nonphospholipase A2 mechanism. J Immunol 1993; 151(4): 2096–104

    PubMed  CAS  Google Scholar 

  33. An S, Goetzl EJ. Lipid mediators of hypersensitivity and inflammation. In: Middleton E, Ellis EF, Adkinson NF, et al., editors. Allergy: principles and practice. St Louis (MO): Mosby, 1998: 168–82

    Google Scholar 

  34. Kahn RM, Okanlami OA, Jacoby DB, et al. Viral infection induces dependence of neuronal M2 muscarinic receptors on cyclooxygenase in guinea pig lung. J Clin Invest 1996; 98(2): 299–307

    Article  PubMed  CAS  Google Scholar 

  35. Sestini P, Armetti L, Gambaro G, et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 1996; 153(2): 572–5

    PubMed  CAS  Google Scholar 

  36. Murray JJ, Mullins MD, Knapp HR, et al. Regulation of the immune response by eicosanoids: pharmacology and clinical effects of prostaglandin E in aspirin-sensitive syndromes. Am J Ther 1995; 2(10): 739–48

    Article  PubMed  Google Scholar 

  37. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. BMJ 1975; 1: 67–9

    Article  PubMed  CAS  Google Scholar 

  38. Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 1990; 3(5): 588–93

    PubMed  CAS  Google Scholar 

  39. Picado C. Aspirin-intolerant asthma: role of cyclooxygenase enzymes. Allergy 2002; 57 Suppl. 72: 58–60

    Article  PubMed  Google Scholar 

  40. Obase Y, Shimoda T, Tomari SY, et al. Effects of pranlukast on chemical mediators in induced sputum on provocation tests in atopic and aspirin-intolerant asthmatic patients. Chest 2002; 121(1): 143–50

    Article  PubMed  CAS  Google Scholar 

  41. Dahlen B, Kumlin M, Margolskee D, et al. The leukotrienereceptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J 1993 Jul; 6(7): 1018–26

    PubMed  CAS  Google Scholar 

  42. Kowalski M, Pawliczak R, Wozniak J, et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med 2000; 161: 391–8

    PubMed  CAS  Google Scholar 

  43. Sanak M, Levy B, Clish C, et al. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 2000; 16: 44–9

    Article  PubMed  CAS  Google Scholar 

  44. Schäfer D, Schmid M, Göde U, et al. Dynamics of eicosanoids in peripheral blood cells during bronchial provocation in aspirin-intolerant asthmatics. Eur Respir J 1999; 13: 638–46

    Article  PubMed  Google Scholar 

  45. Sousa A, Pfister R, Christie PE, et al. Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma. Thorax 1997; 52(11): 940–5

    Article  PubMed  CAS  Google Scholar 

  46. Picado C, Bioque G, Roca-Ferrer J, et al. Nuclear factorkappaB activity is down-regulated in nasal polyps from aspirin-sensitive asthmatics. Allergy 2003; 58(2): 122–6

    Article  PubMed  CAS  Google Scholar 

  47. Picado C, Fernandez-Morata J, Juan M,etal. Cyclo-oxygenase-2 mRNA is downexpressed in nasal polyps from aspirinsensitive asthmatics. Am J Respir Crit Care Med 1999; 160: 291–6

    PubMed  CAS  Google Scholar 

  48. Bennett A. The importance of COX-2 inhibition for aspirin induced asthma. Thorax 2000; 55 Suppl. 2: S54–6

    Article  PubMed  Google Scholar 

  49. Szczeklik A, Nizankowska E, Dworski R. Choline magnesium trisalicylate in patients with aspirin-induced asthma. Eur Respir J 1990 May; 3(5): 535–9

    PubMed  CAS  Google Scholar 

  50. Szczeklik A, Nizankowska E, Bochenek G, et al. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001; 31(2): 219–25

    Article  PubMed  CAS  Google Scholar 

  51. Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001; 108(1): 47–51

    Article  PubMed  CAS  Google Scholar 

  52. Martin-Garcia C, Hinojosa M, Berges P, et al. Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 2002; 121(6): 1812–7

    Article  PubMed  CAS  Google Scholar 

  53. Stevenson DD, Lewis RA. Proposed mechanisms of aspirin sensitivity reactions. J Allergy Clin Immunol 1987; 80(6): 788–90

    Article  PubMed  CAS  Google Scholar 

  54. Higashi N, Taniguchi M, Mita H, et al. A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. Clin Exp Allergy 2002; 32(10): 1484–90

    Article  PubMed  CAS  Google Scholar 

  55. Fischer AR, Rosenberg MA, Lilly CM, et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 1994; 94 (6 Pt 1): 1046–56

    Article  PubMed  CAS  Google Scholar 

  56. O’Sullivan S, Dahlen B, Dahlen SE, et al. Increased urinary excretion of the prostaglandin D2 metabolite 9 alpha, 11 betaprostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J Allergy Clin Immunol 1996; 98(2): 421–32

    Article  PubMed  Google Scholar 

  57. Mita H, Endoh S, Kudoh M, et al. Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma. Allergy 2001; 56(11): 1061–7

    Article  PubMed  CAS  Google Scholar 

  58. Bochenek G, Nagraba K, Nizankowska E, et al. A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol 2003; 111(4): 743–9

    Article  PubMed  CAS  Google Scholar 

  59. Pavord ID, Tattersfield AE. Bronchoprotective role for endogenous prostaglandin E2. Lancet 1995; 345(8947): 436–8

    Article  PubMed  CAS  Google Scholar 

  60. Bianco S, Robuschi M, Damonte C, et al. Bronchial response to nonsteroidal anti-inflammatory drugs in asthmatic patients. Prog Biochem Pharmacol 1985; 20: 132–42

    PubMed  CAS  Google Scholar 

  61. Crimi N, Palermo F, Polosa R, et al. Effect of indomethacin on adenosine-induced bronchoconstriction. J Allergy Clin Immunol 1989; 83(5): 921–5

    Article  PubMed  CAS  Google Scholar 

  62. Field PI, Simmul R, Bell SC, et al. Evidence for opioid modulation and generation of prostaglandins in sulphur dioxide (SO)2-induced bronchoconstriction. Thorax 1996; 51(2): 159–63

    Article  PubMed  CAS  Google Scholar 

  63. Fish JE, Ankin MG, Adkinson Jr NF, et al. Indomethacin modification of immediate-type immunologic airway responses in allergic asthmatic and non-asthmatic subjects: evidence for altered arachidonic acid metabolism in asthma. Am Rev Respir Dis 1981; 123(6): 609–14

    PubMed  CAS  Google Scholar 

  64. Curzen N, Rafferty P, Holgate ST. Effects of a cyclo-oxygenase inhibitor, flurbiprofen, and an H1 histamine receptor antagonist, terfenadine, alone and in combination on allergen induced immediate bronchoconstriction in man. Thorax 1987; 42(12): 946–52

    Article  PubMed  CAS  Google Scholar 

  65. O’Connor BJ, Barnes PJ, Chung KF. Inhibition of sodium metabisulphite induced bronchoconstriction by frusemide in asthma: role of cyclooxygenase products. Thorax 1994; 49(4): 307–11

    Article  PubMed  Google Scholar 

  66. Phillips GD, Holgate ST. The effect of oral terfenadine alone and in combination with flurbiprofen on the bronchoconstrictor response to inhaled adenosine 5′-monophosphate in nonatopic asthma. Am Rev Respir Dis 1989; 139(2): 463–9

    Article  PubMed  CAS  Google Scholar 

  67. Wang M, Wisniewski A, Pavord I, et al. Comparison of three inhaled non-steroidal anti-inflammatory drugs on the airway response to sodium metabisulphite and adenosine 5′-monophosphate challenge in asthma. Thorax 1996; 51(8): 799–804

    Article  PubMed  CAS  Google Scholar 

  68. Sestini P, Refini RM, Pieroni MG, et al. Protective effect of inhaled lysine acetylsalicylate on allergen-induced early and late asthmatic reactions. J Allergy Clin Immunol 1997; 100(1): 71–7

    Article  PubMed  CAS  Google Scholar 

  69. Mitchell JA, Belvisi MG. Too many COX (cyclo-oxygenase) spoil the broth: aspirin-sensitive asthma and 5-lipoxygenase. Thorax 1997; 52(11): 933–5

    Article  PubMed  CAS  Google Scholar 

  70. Mitchell JA, Saunders M, Barnes PJ, et al. Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: role of arachidonic acid. Mol Pharmacol 1997; 51(6): 907–12

    PubMed  CAS  Google Scholar 

  71. Holtzman MJ, Turk J, Shornick LP. Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells. J Biol Chem 1992; 267(30): 21438–45

    PubMed  CAS  Google Scholar 

  72. Claria D, Sherhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A 1995; 92: 9475–9

    Article  PubMed  CAS  Google Scholar 

  73. Dahlen B, Dahlen SE. Leukotrienes as mediators of airway obstruction and inflammation in asthma. Clin Exp Allergy 1995; 25 Suppl. 2: 50–4

    Article  PubMed  Google Scholar 

  74. Pauls JD, Simon RA, Daffern PJ, et al. Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol 2000 Jul; 85(1): 40–5

    Article  PubMed  CAS  Google Scholar 

  75. Antczak A, Montuschi P, Kharitonov S, et al. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med 2002; 166(3): 301–6

    Article  PubMed  Google Scholar 

  76. Picado C, Ramis I, Rosello J, et al. Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. Am Rev Respir Dis 1992; 145(1): 65–9

    Article  PubMed  CAS  Google Scholar 

  77. Ziroli NE, Na H, Chow JM, et al. Aspirin-sensitive versus nonaspirin-sensitive nasal polyp patients: analysis of leukotrienes/ Fas and Fas-ligand expression. Otolaryngol Head Neck Surg 2002; 126(2): 141–6

    Article  PubMed  Google Scholar 

  78. Celik G, Bavbek S, Misirligil Z, et al. Release of cysteinyl leukotrienes with aspirin stimulation and the effect of prostaglandin E (2) on this release from peripheral blood leucocytes in aspirin-induced asthmatic patients. Clin Exp Allergy 2001; 31(10): 1615–22

    Article  PubMed  CAS  Google Scholar 

  79. Penrose JF, Spector J, Baldasaro M, et al. Molecular cloning of the gene for human leukotriene C4 synthase: organization, nucleotide sequence, and chromosomal localization to 5q 35. J Biol Chem 1996; 271(19): 11356–61

    Article  PubMed  CAS  Google Scholar 

  80. Tornhamre S, Ehnhage A, Kolbeck KG, et al. Uncoupled regulation of leukotriene C4 synthase in platelets from aspirinintolerant asthmatics and healthy volunteers after aspirin treatment. Clin Exp Allergy 2002; 32(11): 1566–73

    Article  PubMed  CAS  Google Scholar 

  81. Sanak M, Simon H-U, Szczerklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997; 350: 1599–60

    Article  PubMed  CAS  Google Scholar 

  82. Szczeklik A, Sanak M, Nizankowska E, et al. Leukotriene C4 synthase genetic polymorphism directs urinary cysteinylleukotriene response to aspirin-challenge in asthma [abstract]. Allergy 1998; 53 Suppl. 43: 61

    Google Scholar 

  83. Asano K, Shiomi T, Hasegawa N, et al. Leukotriene C4 synthase gene A (−444)C polymorphism and clinical response to a CYS-LT (1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 2002 Oct; 12(7): 565–70

    Article  PubMed  CAS  Google Scholar 

  84. Sanak M, Szczeklik A. Genetics of aspirin induced asthma. Thorax 2000; 55 Suppl. 2: S45–7

    Article  PubMed  Google Scholar 

  85. Sampson AP, Siddiqui S, Buchanan D, et al. Variant LTC (4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000; 55 Suppl. 2: S28–31

    Article  PubMed  Google Scholar 

  86. Kawagishi Y, Mita H, Taniguchi M, et al. Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J Allergy Clin Immunol 2002; 109(6): 936–42

    Article  PubMed  CAS  Google Scholar 

  87. Arm JP, O’Hickey SP, Spur BW, et al. Airway responsiveness to histamine and leukotriene E4 in subjects with aspirininduced asthma. Am Rev Respir Dis 1989; 140(1): 148–53

    Article  PubMed  CAS  Google Scholar 

  88. Sousa AR, Parikh A, Scadding G, et al. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirinsensitive rhinosinusitis. N Engl J Med 2002; 347(19): 1493–9

    Article  PubMed  CAS  Google Scholar 

  89. Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and proresolution. Prostaglandins Other Lipid Mediat 2002; 68-69: 433–55

    Article  Google Scholar 

  90. Levy BD, Serhan CN. Polyisoprenyl phosphates: natural antiinflammatory lipid signals. Cell Mol Life Sci 2002; 59(5): 729–41

    Article  PubMed  CAS  Google Scholar 

  91. Evsyukova HV. Aspirin-sensitive asthma due to diffuse neuroendocrine system pathology. Neuroendocrinol Lett 2002; 23(4): 281–5

    PubMed  CAS  Google Scholar 

  92. Evsiukova EV, Khavinson VK, Trofimov VI, et al. Epifamine efficacy in aspirin bronchial asthma. Klin Med (Mosk) 2001; 79(9): 61–4

    CAS  Google Scholar 

  93. Tattersfield A, Knox A, Britton J, et al. Asthma. Lancet 2002; 360: 1313–22

    Article  PubMed  CAS  Google Scholar 

  94. Angus RM. Inhaled corticosteroids (budesonide): the cornerstone of asthma therapy: what are the options? Pulm Pharmacol Ther 2002; 15(6): 479–84

    Article  PubMed  CAS  Google Scholar 

  95. Riccioni G, Santilli F, D’Orazio N, et al. The role of antileukotrienes in the treatment of asthma. Int J Immunopathol Pharmacol 2002; 15(3): 171–82

    PubMed  CAS  Google Scholar 

  96. Dahlen SE, Malmström K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist. Am J Respir Crit Care Med 2002; 165: 9–14

    PubMed  Google Scholar 

  97. Dahlen B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998; 157 (4 Pt 1): 1187–94

    PubMed  CAS  Google Scholar 

  98. Orea SM, Flores SG, Machado CF, et al. Aspirin induced asthma, urinary leukotriene E4 and zafirlukast. Rev Alerg Mex 2002; 49(2): 52–6

    Google Scholar 

  99. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SKª 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991; 144(4): 957–8

    Article  PubMed  CAS  Google Scholar 

  100. Yamamoto H, Nagata M, Kuramitsu K, et al. Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. Am J Respir Crit Care Med 1994; 150(1): 254–7

    PubMed  CAS  Google Scholar 

  101. Nasser SM, Bell GS, Foster S, et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax 1994; 49(8): 749–56

    Article  PubMed  CAS  Google Scholar 

  102. Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148 (6 Pt 1): 1447–51

    Article  PubMed  CAS  Google Scholar 

  103. Berges-Gimeno MP, Simon RA, Stevenson DD. The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Clin Exp Allergy 2002; 32(10): 1491–6

    Article  PubMed  CAS  Google Scholar 

  104. Pauls JD, Simon RA, Daffern PJ, et al. Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol 2000 Jul; 85(1): 40–5

    Article  PubMed  CAS  Google Scholar 

  105. Volkman JA, Pontikes PJ. Leukotriene modifiers to prevent aspirin-provoked respiratory reactions in asthmatics. Ann Pharmacother 2002; 36(9): 1457–61

    Article  PubMed  CAS  Google Scholar 

  106. Tang MBY, Yosipovitch G. Acute Churg-Strauss syndrome in an asthmatic patient receiving montelukast therapy. Arch Dermatol 2003; 139(6): 715–8

    Article  PubMed  Google Scholar 

  107. Guilpain P, Viallard JF, Lagarde P, et al. Churg-Strauss syndrome in two patients receiving montelukast. Rheumatology (Oxford) 2002; 41(5): 535–9

    Article  CAS  Google Scholar 

  108. Jamaleddine G, Diab K, Tabbarah Z, et al. Leukotriene antagonists and the Churg-Strauss syndrome. Semin Arthritis Rheum 2002; 31(4): 218–27

    Article  PubMed  CAS  Google Scholar 

  109. Garcia-Marcos L, Schuster A. Antileukotrienes in asthma: present] situation. Expert Opin Pharmacother 2001; 2(3): 441–66

    Article  PubMed  CAS  Google Scholar 

  110. Katsura T, Yoshida F, Takinishi Y. The Churg-Strauss syndrome after pranlukast treatment in a patient not receiving corticosteroids. Ann Intern Med 2003; 139(5): 386–7

    PubMed  Google Scholar 

  111. Kobayashi S, Ishizuka S, Tamura N, et al. Churg-Strauss syndrome in a patient receiving pranlukast. Clin Rheumatol 2003 Dec; 22(6): 491–2

    Article  PubMed  Google Scholar 

  112. Bochenek G, Swierczynska M, Nizankowska-Mogilnicka E, et al. Tolerability of asacard: controlled-release aspirin and aspirin-induced asthma. Pol Arch Med Wewn 2002; 107(3): 249–56

    PubMed  Google Scholar 

  113. Karakaya G, Kalyoncu AF. Paracetamol and asthma. Expert Opin Pharmacother 2003; 4(1): 13–21

    Article  PubMed  CAS  Google Scholar 

  114. Szczeklik A, Nizankowska E, Mastalerz L, et al. Analgesics and asthma. Am J Ther 2002; 9(3): 233–43

    Article  PubMed  Google Scholar 

  115. Woessner KM, Simon RA, Stevenson DD. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum 2002; 46(8): 2201–6

    Article  PubMed  CAS  Google Scholar 

  116. Bingham III CO. Development and clinical application of COX-2-selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis. Cleve Clin J Med 2002; 69 Suppl. 1: SI5–12

    Article  Google Scholar 

  117. Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2003; 111(1): 180–6

    Article  PubMed  CAS  Google Scholar 

  118. Berges-Gimeno MP, Simon RA, Stevenson DD. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2003; 90(3): 338–41

    Article  PubMed  CAS  Google Scholar 

  119. Gosepath J, Schafer D, Mann WJ. Aspirin sensitivity: long term follow-up after up to 3 years of adaptive desensitization using a maintenance dose of 100mg of aspirin a day. Laryngorhinootologie 2002; 81(10): 732–8

    Article  PubMed  CAS  Google Scholar 

  120. Juergens UR, Christiansen SC, Stevenson DD, et al. Inhibition of monocyte leukotriene B4 production after aspirin desensitization. J Allergy Clin Immunol 1995; 96(2): 148–56

    Article  PubMed  CAS  Google Scholar 

  121. Nasser SM, Patel M, Bell GS, et al. The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma. Am J Respir Crit Care Med 1995; 151(5): 1326–30

    PubMed  CAS  Google Scholar 

  122. Amayasu H, Nakabayashi M, Akahori K, et al. Cromolyn sodium suppresses eosinophilic inflammation in patients with aspirin-intolerant asthma. Ann Allergy Asthma Immunol 2001; 87(2): 146–50

    Article  PubMed  CAS  Google Scholar 

  123. Szczeklik A, Dworski R, Mastalerz L, et al. Salmeterol prevents aspirin-induced attacks of asthma and interferes with eicosanoid metabolism. Am J Respir Crit Care Med 1998; 158(4): 1168–72

    PubMed  CAS  Google Scholar 

  124. Taylor IK, O’Shaughnessy KM, Choudry NB, et al. A comparative study in atopic subjects with asthma of the effects of salmeterol and salbutamol on allergen-induced bronchoconstriction, increase in airway reactivity, and increase in urinary leukotriene E4 excretion. J Allergy Clin Immunol 1992; 89(2): 575–83

    Article  PubMed  CAS  Google Scholar 

  125. Tries S, Neupert W, Laufer S. The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2. Inflamm Res 2002; 51(3): 135–43

    Article  PubMed  CAS  Google Scholar 

  126. Gray PA, Warner TD, Vojnovic I, etal. Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors. Br J Pharmacol 2002; 137(7): 1031–8

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Dr Hamad is supported by a grant from the Wellcome Trust. No other sources of funding were used to assist in the prepration of this review. The authors have no conflicts of interest to declare.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alan J. Knox.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hamad, A.M., Sutcliffe, A.M. & Knox, A.J. Aspirin-Induced Asthma. Drugs 64, 2417–2432 (2004). https://doi.org/10.2165/00003495-200464210-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200464210-00004

Keywords

Navigation